Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Eleda Infra Services Group (“Eleda”) on the acquisition of Mats Wåhlin AB (”MWAB”)
Mandate

Vinge has advised Eleda Infra Services Group (“Eleda”) on the acquisition of Mats Wåhlin AB (”MWAB”)

March 08, 2022 Banking and Finance M&A Corporate Crime & Compliance Commercial Agreements Employment and Benefits

MWAB is based in Stockholm and specialises in diving and maritime constructions in confined and contaminated environments for customers in the public sector, as well as private contractors. The company has over 40 years’ experience and a turnover of approximately SEK 35 million on an annual basis.

Vinge’s team consisted primarily of partner Christina Kokko and associates Manne Bergström and Carl Fredrik Wachtmeister (M&A), Ellen Åkerdahl Flygt (M&A and Banking & Finance), Isak Willborg (Agreements), Elin Broman (Employment), Tove Tullberg (Compliance), Sara Dahlros Sköld and Elin Kollin (VDR-assistants).

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025